The introduction of antivascular endothelial growth factor (anti-VEGF) agents has dramatically altered the therapeutic landscape of retinal diseases, including neovascular age-related macular degeneration, diabetic macular edema (DME), and retinal vein occlusions (RVO). Despite their clinical success, the financial burden associated with innovator biologics such as ranibizumab and aflibercept remains a significant barrier, particularly in low- and middle-income countries. In this setting, biosimilars have gained attention as a potentially transformative solution. However, an important debate persists: do these agents deliver comparable outcomes or do they entail compromises in efficacy and safety? Biosimilars are complex biologic products developed to closely match an already approved reference molecule in terms of structural characteristics, biological activity, and clinical performance. Regulatory approval requires stringent analytical comparison and clinical validation, often through noninferiority trials. One of the most compelling advantages of biosimilars is their reduced cost – frequently 50%–60% lower than originator drugs – thereby improving affordability and access for a broader patient population. In ophthalmology, real-world data (RWD) play a pivotal role, as many retinal conditions necessitate prolonged treatment, and patient adherence is strongly influenced by financial constraints. Emerging evidence from routine clinical practice across India and other Asian regions indicates that biosimilar ranibizumab demonstrates outcomes comparable to its reference counterpart. For example, the large-scale ROSE Korea study, which included over 1100 treated eyes, reported meaningful reductions in central macular thickness along with stabilization or improvement in visual acuity over a 1-year follow-up period. Importantly, the treatment was well tolerated, with a low incidence of adverse events. Supporting these findings, the Indian BRESER study evaluated biosimilar ranibizumab (Ranieyes) across multiple indications, including DME, macular neovascularization, and RVO. Patients experienced significant visual improvement, with DME cases showing gains from approximately 6/36 to 6/15. These functional and anatomical outcomes closely align with those reported in landmark trials of innovator anti-VEGF therapies. Safety remains a key consideration in the adoption of biosimilars. Encouragingly, current real-world reports suggest that both ocular and systemic adverse events occur at rates similar to those seen with reference biologics. No new or unexpected safety concerns have emerged in large patient cohorts. Nevertheless, as with all biologic therapies, ongoing pharmacovigilance and long-term monitoring are essential to ensure continued safety. Despite the growing body of supportive evidence, certain challenges remain. Much of the available RWD are derived from retrospective analyses with variable treatment regimens and relatively limited follow-up durations. In addition, concerns regarding interchangeability and the absence of robust switching studies contribute to clinician hesitation. Surveys indicate that practitioners often rely more heavily on postmarketing data than preapproval trials, underscoring the importance of continued real-world research. From a broader healthcare perspective, biosimilars offer substantial socioeconomic benefits. By lowering treatment costs, they can enhance patient adherence, enable more consistent dosing, and ultimately reduce the burden of preventable vision loss. This is especially relevant in India, where a large proportion of healthcare expenses are borne directly by patients. In summary, current evidence suggests that biosimilars represent not a compromise, but a pragmatic and effective alternative in the management of retinal diseases. While further long-term and high-quality comparative studies are warranted, existing RWD support their integration into routine practice. Biosimilars may thus play a crucial role in improving accessibility and sustainability in retinal care.
S.D. Paul (Tue,) studied this question.